Background Current systemic treatments for atopic dermatitis (AD) offer limited efficacy and
are often restricted by safety concerns. Biologics may address the unmet need for improved …

Background Cross‐sectional data on patient burden in adults with atopic dermatitis (AD)
from real‐world clinical practice are limited. Objective This study compared patient‐reported …

Background and aims The high number of negative opinions from the European Food Safety
Authority (EFSA) to the requests for authorization of health claims is largely due to the …

Background X-linked hypohidrotic ectodermal dysplasia (XLHED) is caused by pathogenic
variants of the gene EDA disrupting the prenatal development of ectodermal derivatives …

Background: Atopic dermatitis (AD) is a common and chronic inflammatory skin disease.
Approximately 10% of adults with AD do not respond adequately to topical therapies and …

Background Numerous inclusion criteria and baseline severity assessments are used in
clinical trials of atopic dermatitis (AD), which may limit comparison of results. Objective We …

Background: Atopic dermatitis (eczema) is a common chronic or recurrent inflammatory skin
disease affects 15–20% of children and 1–3% of adults worldwide. It is characterized by …